Canaccord Genuity Reiterates Buy Rating on Hims & Hers Health, Inc.
Canaccord Genuity maintains a buy rating on Hims & Hers Health, Inc. with a $40 price target, a 4.85% upside from the current price.
Key Points
- Canaccord Genuity reiterated its buy rating on Hims & Hers Health, Inc. (NYSE:HIMS) with a $40 price target on July 1, 2026.
- Canaccord Genuity's $40 price target implies 4.85% upside from Hims & Hers Health, Inc.'s ($HIMS) current $38.15 share price.
- Shares of HIMS traded at $34.17 on Wednesday, with a market cap of $8.02 billion and a forward P/E ratio of 39.0.
- Insider transactions include planned sales by the CFO and CTO, while analysts like B of A Securities and Barclays also maintain their ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Canaccord Genuity reiterated its buy rating on Hims & Hers Health, Inc. (NYSE:HIMS), setting a price target of $40. Shares of the company traded at $34.17 on Wednesday.
Canaccord Genuity vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Hims & Hers Health, Inc. Stock Up 32.3%
Shares of NYSE:HIMS traded near $34.17 on Wednesday. The company has a market cap of approximately $8.02 billion and a forward P/E ratio of 39.0. With a beta of 2.398, the stock has experienced a 52-week low of $13.74 and a high of $70.43. Its 50-day moving average stands at $27.97, while the 200-day moving average is $32.92.
$HIMS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Hims & Hers Health, Inc.
Several insider transactions took place recently. On June 22, 2026, Chief Financial Officer Oluyemi Okupe sold 18,197 shares at an average price of $34.03 under a planned sale. On the same day, Okupe also sold an additional 6,376 shares without a plan and purchased 6,376 shares at $5.01. Chief Medical Officer Patrick Harrison Carroll sold 23,726 shares at $35.00 on June 18, 2026, under a planned sale. CTO Mohamed Elshenawy and PAO Irene Becklund also made planned sales on June 17, 2026.
Analysts Set New Price Targets
On July 1, 2026, Canaccord Genuity maintained its buy rating with a $40 price target for Hims & Hers Health, Inc. B of A Securities also maintained a hold rating with a $36 target. Earlier, on June 18, 2026, Barclays maintained a buy rating with a $39 price target. The consensus among analysts is a hold rating with a mean target price of $27.32, based on 14 opinions.
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. is a healthcare platform based in San Francisco, California. It connects consumers with licensed healthcare professionals and offers a range of health and wellness products. These include prescription and non-prescription products, cosmetics, and supplements. The company operates in several countries, including the U.S., U.K., and Canada, and is led by CEO Andrew Dudum.
Bottom Line
Hims & Hers Health, Inc. continues to draw attention from analysts, with Canaccord Genuity reiterating its buy rating and setting a $40 price target. The company's stock performance shows volatility, reflected in its high beta and wide 52-week range. Investors keep a close eye on insider transactions and analyst ratings to gauge market sentiment. Remember, the ratings and targets are based on past data and may not reflect the current market conditions.
Get Hims & Hers Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HIMS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.